Infervision is a Chinese company that develops artificial intelligence–based medical imaging solutions for healthcare providers. The firm’s core product set centers on AI tools for interpreting medical images to support diagnostics and clinical workflows. The article reports a new investment that increased the company’s Series D haul to nearly 900 million yuan (about $139 million). The coverage does not disclose operating metrics, customers, or specific product names. No future product plans or timelines are detailed in the article. The company is positioned as an AI medical‑imaging vendor operating in China. Infervision develops AI-driven medical imaging products aimed at diagnosing lung cancer, cerebral artery infarction and other conditions. Its lung cancer diagnostic AI is described as relatively mature and being readied for active hospital use after feature additions. The company has applied its cerebral artery infarction program in several cerebral stroke research centers, while AI-assisted cardiac screening, fracture screening, liver-related abdominal products and AI-assisted breast cancer screening are in test phases. Infervision has deployed systems in seven hospitals on Fudan University's Top 10 Hospitals List and partnered with half on the university's Top 50 Hospitals List, serving about 450,000 patients. Last year it launched operations in Shanghai, Wuhan, Dalian and Guangzhou to expand nationwide and has set up offices in the US, Japan and Germany, with its system installed in a Japanese hospital. The company plans to continue developing, producing and internationally marketing its AI medical imaging products.

Total raised

$186M

Funding rounds

2

Latest round

Series D

Latest activity

Jul 2021